These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Emerging drugs for hepatitis C. Soriano V; Madejon A; Vispo E; Labarga P; Garcia-Samaniego J; Martin-Carbonero L; Sheldon J; Bottecchia M; Tuma P; Barreiro P Expert Opin Emerg Drugs; 2008 Mar; 13(1):1-19. PubMed ID: 18321145 [TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Borgia G; Maraolo AE; Buonomo AR; Scotto R; Gentile I Expert Opin Investig Drugs; 2016 Oct; 25(10):1209-14. PubMed ID: 27537604 [TBL] [Abstract][Full Text] [Related]
4. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Durantel D; Alotte C; Zoulim F Curr Opin Investig Drugs; 2007 Feb; 8(2):125-9. PubMed ID: 17328228 [TBL] [Abstract][Full Text] [Related]
5. Development of novel treatments for hepatitis C. Webster DP; Klenerman P; Collier J; Jeffery KJ Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226 [TBL] [Abstract][Full Text] [Related]
6. Investigational drugs for hepatitis C. Flisiak R; Parfieniuk A Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555 [TBL] [Abstract][Full Text] [Related]
7. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911 [TBL] [Abstract][Full Text] [Related]
8. 5th Antiviral Drug Discovery and Development Summit. Blair W; Perros M Expert Opin Investig Drugs; 2004 Aug; 13(8):1065-9. PubMed ID: 15268642 [TBL] [Abstract][Full Text] [Related]
9. Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents? Narjes F; Koch U; Steinkühler C Expert Opin Investig Drugs; 2003 Feb; 12(2):153-63. PubMed ID: 12556211 [TBL] [Abstract][Full Text] [Related]
11. Challenges and successes in developing new therapies for hepatitis C. De Francesco R; Migliaccio G Nature; 2005 Aug; 436(7053):953-60. PubMed ID: 16107835 [TBL] [Abstract][Full Text] [Related]
12. Current and future concepts in hepatitis C therapy. Pawlotsky JM Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999 [TBL] [Abstract][Full Text] [Related]
13. The design of drugs for HIV and HCV. De Clercq E Nat Rev Drug Discov; 2007 Dec; 6(12):1001-18. PubMed ID: 18049474 [TBL] [Abstract][Full Text] [Related]
15. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. Brown NA Expert Opin Investig Drugs; 2009 Jun; 18(6):709-25. PubMed ID: 19426125 [TBL] [Abstract][Full Text] [Related]
17. Agents and strategies in development for improved management of herpes simplex virus infection and disease. Kleymann G Expert Opin Investig Drugs; 2005 Feb; 14(2):135-61. PubMed ID: 15757392 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in the discovery of small molecule therapies for HCV. Myles DC Curr Opin Drug Discov Devel; 2001 Jul; 4(4):411-6. PubMed ID: 11727306 [TBL] [Abstract][Full Text] [Related]